Investors

Press Releases

Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
Endonovo to Donate SofPulse® Units for Investigational Use to Evaluate Inhibition of Inflammatory Symptoms Associated with COVID-19
Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®
Endonovo Therapeutics Introduces Support of SofPulse® With A New Ancillary Multi-Use Patient Brace From Protex
Endonovo Therapeutics Begins Process For Medical Reimbursements
Endonovo Therapeutics Announces collaborating with a Stanford University sponsored Orthopedic Shoulder and Knee Study
RSS
Show All